Martínez-García, M.; Velasco, G.; Pineda, E.; Gil-Gil, M.; Alameda, F.; Capellades, J.; Martín-Soberón, M.C.; López-Valero, I.; Tovar Ambel, E.; Foro, P.;
et al. Safety and Efficacy of Crizotinib in Combination with Temozolomide and Radiotherapy in Patients with Newly Diagnosed Glioblastoma: Phase Ib GEINO 1402 Trial. Cancers 2022, 14, 2393.
https://doi.org/10.3390/cancers14102393
AMA Style
Martínez-García M, Velasco G, Pineda E, Gil-Gil M, Alameda F, Capellades J, Martín-Soberón MC, López-Valero I, Tovar Ambel E, Foro P,
et al. Safety and Efficacy of Crizotinib in Combination with Temozolomide and Radiotherapy in Patients with Newly Diagnosed Glioblastoma: Phase Ib GEINO 1402 Trial. Cancers. 2022; 14(10):2393.
https://doi.org/10.3390/cancers14102393
Chicago/Turabian Style
Martínez-García, María, Guillermo Velasco, Estela Pineda, Miguel Gil-Gil, Francesc Alameda, Jaume Capellades, Mari Cruz Martín-Soberón, Israel López-Valero, Elena Tovar Ambel, Palmira Foro,
and et al. 2022. "Safety and Efficacy of Crizotinib in Combination with Temozolomide and Radiotherapy in Patients with Newly Diagnosed Glioblastoma: Phase Ib GEINO 1402 Trial" Cancers 14, no. 10: 2393.
https://doi.org/10.3390/cancers14102393
APA Style
Martínez-García, M., Velasco, G., Pineda, E., Gil-Gil, M., Alameda, F., Capellades, J., Martín-Soberón, M. C., López-Valero, I., Tovar Ambel, E., Foro, P., Taus, Á., Arumi, M., Hernández-Laín, A., & Sepúlveda-Sánchez, J. M.
(2022). Safety and Efficacy of Crizotinib in Combination with Temozolomide and Radiotherapy in Patients with Newly Diagnosed Glioblastoma: Phase Ib GEINO 1402 Trial. Cancers, 14(10), 2393.
https://doi.org/10.3390/cancers14102393
